Do‐Youn Oh

机构：Seoul National University, Seoul National University Hospital · ORCID：0000-0003-1663-9901

发表论文 958 篇 · 总被引 45373 次 · h-index 82

代表论文

• Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer (2025 · JAMA Oncology · 被引 7)
• Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma (2025 · Clinical Cancer Research · 被引 4)
• Fadraciclib, a CDK2/CDK9 inhibitor, shows efficacy in biliary tract cancer and synergistic potential with olaparib and JQ1 based on MCL1 expression (2025 · Cell Communication and Signaling · 被引 2)
• Data from <i>Post Hoc</i> Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors (2026 · 被引 1)
• Open-label, single-arm, phase II trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer (2025 · Journal of Hepatology · 被引 1)
• [177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial (2026 · EClinicalMedicine)